GNTbm’s self-developed anti-cancer new drug GNTbm-38 has obtained IND approval from the U.S. FDA for Phase I clinical trials

2026-03-05 - 13:37

TAIPEI, March 5, 2026 /PRNewswire/ — Great Novel Therapeutics Biotech & Medicals Corporation (GNTbm) (stock code: 7427) announced that its independently developed novel epigenetic immunoactivator GNTbm-38, with global rights for cancer immunotherapy, has received approval from the U.S. FDA for its IND application and will proceed with patient enrollment for a Phase I clinical trial